Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703)

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

Related Keywords

Poland ,Austria ,Vienna ,Wien ,Warsaw ,L67 ,Hendrik Nogai ,Menarini Group ,European Hematology Association ,Warsaw Stock Exchange ,Ongoing Phase ,Dose Escalation Study ,Annual European Hematology Association ,Chief Medical Officer ,Clinical Signs ,Mutation Positive ,Derived Cells ,Efficacy Data ,First In Class Dual ,Mutated Acute Myeloid Leukemia ,Ryvu Therapeutics ,